Close Menu

NEW YORK – DNAnexus said Tuesday that it has completed a $100 million financing round, led by Perceptive Advisors and Northpond Ventures. Previous investors GV, Foresite Capital, TPG Capital, and First Round Capital participated, as did new backer Regeneron Pharmaceuticals.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.